Tuesday night we learn whether AAPL’s earnings can lead the QQQ through resistance.
Meanwhile the bio-techs continue to show strength. My readers know that I rarely buy cheap stocks. I do make an exception when my extraordinary stock picker buddy, Judy, tells me about a small, young company that has a promising product. Enter NVIV and its spine tingling surgical implant (pun intended). She, and then I, have been nibbling at NVIV. The company has created a medical device that has shown some early unexpectedly good results. The company also has a very good medical pedigree. NVIV is very speculative, but when I look at the volume spikes on this daily chart, it is clear that there is some major buying interest. At $2.09 per share, it is probably a better use for my money than buying a lottery ticket…..